Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging
Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging
The routine administration of 75 mg of intravenous aminophylline in patients with severe
 chronic kidney disease undergoing a nuclear stress test with regadenoson (Lexiscan®) can
 reduce or eliminate the incidence of diarrhea and other side effects related to regadenoson.
Approximately 300 patients with severe chronic kidney disease who are referred for a nuclear
 stress testing of the heart with regadenoson (Lexiscan®) will be recruited to participate in
 the study. Following regadenoson (administered as part of a stress routine test protocol)
 participants will receive either aminophylline (75 mg - intravenously) or a matching inactive
 placebo (sterile salt water) injection. Participants will be surveyed for gastrointestinal
 symptoms and other side effects related to regadenoson. The frequency and severity of such
 side effects will be compared between the two study groups (aminophylline vs. placebo).
Inclusion Criteria:

 -  Adult patients referred to undergo a clinically-indicated regadenoson-stress
 myocardial perfusion imaging at Rush University Medical Center

 -  Stage IV or V chronic kidney disease (GFR < 30, hemodialysis, and/or peritoneal
 dialysis).

 Exclusion Criteria:

 -  Patient refusal to participate

 -  Known allergic reaction to aminophylline.

 -  Pre-existing headache or acute/subacute GI illness with symptoms of diarrhea,
 abdominal discomfort, nausea or vomiting.

 -  Any contraindication to aminophylline: hypotension, unstable cardiac arrhythmias and
 acute coronary symptoms.

 -  Uncontrolled seizure disorder defined as more than 2 seizure episodes in the past 12
 months or any seizure in the past week.

 -  Pregnant or breast-feeding women.

 -  Patients receiving anti-platelet agent dipyridamole (Persantine® or Aggrenox®).